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Abstract The intra-arterial injection of immortalized microglia
transfected with the lacZ gene, resulted in the expression of
L-galactosidase in the rat brain at 48 h and the activity of
L-galactosidase was detected for up to 3 weeks post-injection.
More than 30-fold higher activity of L-galactosidase was
detected in the brain than in the liver, lung or spleen at 48 h
post-injection. This method allows us to easily deliver the gene of
interest to the brain without influencing other organs. Our brain-
targeting gene delivery system can facilitate gene therapy of
several brain disorders, including brain tumor, metabolic
disorders, and degenerative disorders, as well as investigation
into the roles of particular genes in brain function and
development.
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1. Introduction
The ability to manipulate the expression of genes within the
mammalian brain provide unique opportunities to study and
to potentially treat neurologic disorders. The introduction of
certain genes speci¢cally in brain has been done with viral
vectors or cells carrying DNA. However, these methods re-
quire surgery. Recently, we found that primary isolated mi-
croglia speci¢cally entered the brain from blood £ow when the
cells were injected intra-arterially [1]. Since intra-arterially in-
jected microglia were labeled with £uorescent dye micropar-
ticles by their phagocytic activity, this system could apply to a
brain-speci¢c delivery for medicines, or other bioactive mate-
rials, such as proteins or genes.
Microglia, macrophage-like cells in the brain, are multi-
functional cells ; they play important roles in the development,
di¡erentiation and maintenance of neural cells via their phag-
ocytic activity and production of enzymes, cytokines and
trophic factors [2]. Although activated microglia show similar
phenotypes to macrophages in isolated conditions, they ap-
pear to display phenotypes di¡ering from macrophages in
vivo and in vitro [3^11]. An example of phenotypic di¡erence
between both types of cells is the a⁄nity and migrating activ-
ity of isolated microglia for the brain [1].
In this paper, we investigated the possibility that microglia
can deliver the gene of interest to brain without any e¡ects to
other organs, by injection of microglia transfected L-galacto-
sidase gene expression vector to a vertebral artery of the rats.
2. Materials and methods
2.1. Cell cultures
Primary mixed glial cell cultures were prepared in Eagle’s MEM
supplemented with 10% fetal calf serum, 5 Wg/ml bovine insulin, and
0.2% glucose from neonatal Fisher rats as described previously [6,12].
Medium was changed every 3 days. Microglia were isolated on the
14th day by mechanical agitation and puri¢ed using non-coated plas-
tic dishes (Falcon 1001, Becton-Dickinson Japan, Tokyo, Japan) as
described previously [6]. The purity of microglia was more than 99%
as determined by immunostaining with FITC-labeled IgG (used in
1:100 dilution, Cappel, West Chester, PA). Ra2 cells, immortalized
microglial clone cells, were maintained in the culture medium de-
scribed above containing 1 ng/ml recombinant mouse GM-CSF (Gen-
zyme, Cambridge, MA). Ra2 cells stop to proliferate without GM-
CSF in vitro, and there was not observed any tumorigenic activity in
brain parenchyma. Procedures for establishment of mouse and rat
microglial cell lines were described in a manuscript submitted else-
where.
2.2. Gene transfection
Twenty four hours prior to transfection, puri¢ed microglia and Ra2
cells were seeded at 5U106 cells in a 10-cm plastic dish (Falcon 3003,
Becton-Dickinson Japan, Tokyo, Japan). Fifteen microgram of pEF1-
Geo, an expression vector of lacZ-neor fusion gene under control of
human EF1 promoter (a kind gift from Dr. Y. Kadokawa, Fujita
Health University) in 0.36 ml of HEPES-bu¡ered saline (20 mM
HEPES, 150 mM NaCl, pH 7.4) was carefully mixed with 0.14 ml
of DOTAP transfection reagent (Boehringer Mannheim Japan, To-
kyo, Japan) by gentle pipetting and stood for 15 min at room temper-
ature. DNA-DOTAP transfection solution was mixed with 6.5 ml
fresh culture medium, then added to the cells in 10-cm dish. After
incubation for 16 h cells were washed twice with 5 ml culture medium,
then incubated another 48 h.
2.3. Fluorescent dye staining
To recognize the exogenous cells within the brain, the cells were
tagged with a lipid-soluble, £uorescent dye, PKH26 [13,14] (Zynaxis
Cell Science, Inc., Malvern, PA). PKH26 stained microglia e⁄ciently;
the puri¢ed microglia were stained with intensity at least two orders
higher than the puri¢ed astrocytes. The cells in a 10-cm plastic dish
were incubated with PKH26 staining solution containing 10 mM of
PKH26, 50% Diluent B (a phagocytic cell-labeling solution, Zynaxis,
Malvern, PA), and 50% culture medium for 15 min, then washed three
times in 10 ml serum-containing medium. PKH26-stained cells were
harvested using a rubber policeman in 2 ml of ice-cold phosphate-
bu¡ered saline (pH 7.2), washed with 5 ml ice-cold phosphate-bu¡-
ered saline (pH 7.2) by centrifugation three times, then 2U106 cells
were injected into a male Fisher rat intra-arterially.
2.4. Intra-arterial injection
Male Fisher rats weighing about 200 g were anesthetized with 42
mg/kg sodium pentobarbital by i.p. injection. Cells were injected into
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the recipient’s subclavian artery. At 2 h, 48 h, 9, 16 and 23 days
following injection, rats were treated with about 200 ml isotonic saline
by intra-aortic perfusion, then the brain, liver, spleen and lung were
isolated, frozen in liquid nitrogen, and embedded in O.C.T. com-
pound (Tissue Tek, Elkhart, IN). Sections (8 Wm) were cut with a
cryostat microtome, transferred to slide glass and dried. Fluorescently
labeled cells were photographed under a £uorescence microscope
(IX70-FLA, Olympus, Tokyo, Japan).
2.5. Detection of L-galactosidase in tissues
The cells expressing L-galactosidase were identi¢ed following incu-
bation with X-gal (5-bromo-4-chloro-3-indolyl-L-galactopyranoside,
Nakalai Tesque, Osaka, Japan). Tissue sections were ¢xed for 15
min in a solution containing 1% glutaraldehyde, 0.1 M sodium phos-
phate bu¡er (pH 7.0), and 1 mM MgCl2, and then incubated with a
solution containing 0.2% X-gal, 10 mM sodium phosphate bu¡er (pH
7.0), 150 mM NaCl, 1 mM MgCl2, 3.3 mM K4Fe(CN)6, and 3.3 mM
K3Fe(CN)6. Following incubation for 6^12 h at 37‡C, the staining
solution was removed, then sections were washed three times by 0.1 M
sodium phosphate bu¡er (pH 7.0), mounted with 70% glycerol, and
photographed.
2.6. Measurement of L-galactosidase activity
The activity of L-galactosidase derived from cells expressing lacZ
gene in tissue section was determined by Galacto-Light chemilumines-
cent assay kit (Tropix, Bedford, MA). Tissue sections were lysed in 0.2
ml lysis solution containing 0.1 M potassium phosphate (pH 7.8),
0.2% Triton X-100 and 1 mM DTT. The lysate was centrifuged for
2 min at 13 000 rpm, and the supernatant was collected. Aliquot 20 Wl
of supernatant was reacted with Galacton chemiluminescent substrate
(100-fold diluted) in 0.2 ml of reaction bu¡er containing 0.1 M so-
dium phosphate bu¡er (pH 8.0) and 1 mM MgCl2. After 60 min
incubation, 0.3 ml accelerator was added and mixed quickly. After
5 s delay following addition, chemiluminescence was measured
by Lumat LB9507 chemiluminometer (Berthold Japan, Tokyo, Ja-
pan).
3. Results and discussion
At 48 h after the £uorescent-labeled puri¢ed microglia were
injected intra-arterially, many £uorescent cells were observed
in the brain section of the rat (Fig. 1A). A higher magni¢ca-
tion shows that a large portion of the £uorescent cells were in
the brain parenchyma including cerebral cortex, hippocampal
region, brainstem and cerebellum, apart from blood capillar-
ies and that some of these £uorescent cells had large processes
(Fig. 1B). A small portion of the £uorescent cells were ob-
served in the brain capillaries, attached on the capillary wall.
Two hours following the injection, migration of microglia into
the brain parenchyma was observed (Fig. 1C). Exogenous
£uorescently labeled microglia were observed to adhere to a
vessel in the brain. Some microglia crossed the vessel and
entered the parenchyma. Similar results were obtained with
Ra2 cells (data not shown). When a frozen brain section
were stained with X-gal as a substrate for exogenously intro-
duced L-galactosidase, many lacZ-positive cells were observed
in the brain from the rats at 48 h after Ra2 which were trans-
fected with a lacZ gene expression vector were injected intra-
arterially (Fig. 1D). Similar results were obtained with puri-
¢ed microglia (data not shown). Therefore, intra-arterially
injected microglia and Ra2 cells can migrate to the brain
and can express the genes transfected in vitro and translate
them into biologically active proteins in the brain.
The speci¢city of Ra2 migration was determined by meas-
uring L-galactosidase activity in the brain and in other tissues.
Using a highly sensitive detection method for L-galactosidase
activity with a chemiluminescent substrate we could detect
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Fig. 1. A, B: Existence of £uorescently labeled microglia in the cerebellar parenchyma of the brain section from the rat at 48 h following in-
tra-arterial injection with puri¢ed microglia. B indicates the higher magni¢cation of the same ¢eld. C: Exogenous microglia that were £uores-
cently labeled were observed to adhere to a vessel in the brain section from the rat at 2 h following intra-arterial injection. Some microglia
have crossed the vessel and have entered the parenchyma. D: Existence of lacZ-positive microglia in the cerebellar parenchyma of the brain
section from the rat at 48 h following intra-arterial injection with Ra2 transfected with a lacZ gene expression vector stained by X-gal as a sub-
strate for L-galactosidase. Bars indicate 100 Wm in A and D, and 50 Wm in B and C.
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L-galactosidase activity in a frozen section with about 8 Wm
thick of brain and other tissues. L-galactosidase activity in
tissues derived from Ra2 cells at 48 h following intra-arterial
injection was highest in the brain; over 30-fold than that in
the liver and spleen and was not detected in the lung sections
(Fig. 2). Therefore, we concluded that most of the injected
Ra2 cells migrated to the brain. These results are consistent
with our previous observation which shows that highly puri-
¢ed microglia from rat mixed brain cultures migrated specif-
ically into the brain, but were rarely found in the liver [1]. On
the other hand, puri¢ed macrophages migrated to liver but
were not found in the brain of normal rats [15]. The data
indicate that microglia have a characteristic di¡ering from
macrophages; the former have a speci¢c a⁄nity and migrat-
ing activity to the brain.
The stability of gene expression in brain was determined by
measuring L-galactosidase activity in brain sections at 2, 9, 16
and 23 days after intra-arterial Ra2 injection. L-galactosidase
activity in the brain sections was highest at 2 days and later
gradually decreased (Fig. 3A). At 23 days the L-galactosidase
activity was about a half of that at 2 days; product of the
transferred gene was still active. Twenty three days after the
injection, the £uorescent Ra2 was still present in the brain
sections in a similar number to that of day 2, although the
£uorescence intensity of Ra2 was much weaker than that of
the day 2 brain section (Fig. 3B). Therefore, decrease of L-ga-
lactosidase activity was seemed to be due to decrease of the
expression of lacZ gene in Ra2 cells because it was transiently
transfected. This means that if Ra2 which expressed the gene
permanently was injected, the genes of interest can be ex-
pressed in the brain for more than 20 days.
Many types of methods and techniques for in vivo gene
transfer have been developed, and some of them have already
been applied in clinical trials. The retroviral system, the most
widely accepted gene transfer method to date, can achieve
highly e⁄cient integration, providing the potential for perma-
nent gene expression. However, the system has some major
disadvantages such as the typically low titer, instability of the
viral vector obtained, and the requirement for target cell di-
vision for integration and expression [16]. The adenoviral sys-
tem can provide more e⁄cient gene transfer and stability of
virus, however, the di⁄culties in control of target cells and of
re-administrations necessitated by the strong antigenicity of
the virus are serious problems [17]. The in vivo electropora-
tion has been demonstrated in highly e⁄cient gene transfer
into the brain [18]. The systems using adeno-associated viruses
and HIV-based vectors as potential vectors are also available
for gene therapy. But all of these methods require a major
surgical procedure to transfer cells carrying genes, or to insert
a stainless steel electrode when they were attempted to apply
for brain disorders.
We found that an intra-arterially injected microglial cell line
migrated speci¢cally into the brain. Using this cell line we
established a technique to carry and express a recombinant
gene speci¢cally into the brain, and not to other tissues, using
only a cannulation in the vertebral artery. With our method,
no major surgical procedure is required. Since microglia are
normally negative for MHC class I and II antigens in vivo,
this brain-targeting gene delivery system can facilitate gene
therapy of several brain disorders, including brain tumor,
metabolic disorders, and degenerative disorders, as well as
investigations into the roles of particular genes in brain func-
tion and development.
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Fig. 3. A: Time-dependent change of the activity of L-galactosidase derived from Ra2 cells expressing lacZ gene in brain sections. The activity
was determined using sections from brains isolated from the rats at 2, 9, 16 and 23 days following intra-arterial injection with 2U106 Ra2 cells.
n = 3. B: Existence of £uorescently labeled Ra2 cells in the cerebellar parenchyma of the brain from the rat at 23 days following intra-arterial
injection with 2U106 Ra2 cells. Bars indicate 100 Wm.
Fig. 2. Distribution of the activity of L-galactosidase derived from
Ra2 cells expressing lacZ gene in tissue sections. The activity was
determined using sections from brain, liver, lung and spleen isolated
from the rats at 48 h following intra-arterial injection with 2U106
Ra2 cells. n = 3.
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